Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Ronald Bailey

Neurology Riverside, CA Medical Doctor

NPI 1104808914 CMS profile 231161

7117 Brockton Ave, Riverside, CA 92506

Open in the dashboard

General payments

$6,333

434 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Ronald Bailey of Riverside, CA is reported in the CMS Open Payments database as having received $6,333 across 434 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $37 2
2021 General $1,697 98
2020 General $2,180 153
2019 General $2,419 181

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Bailey
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ronald Bailey were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ronald Bailey Neurology median Middle half National median
2019 $2,419 $474 $118–$2,177 $163
2020 $2,180 $367 $82–$2,309 $114
2021 $1,697 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $37 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Alexion Pharmaceuticals, Inc. $1,015 84 payments
  2. Mallinckrodt Hospital Products Inc. $939 53 payments
  3. Genentech USA, Inc. $567 35 payments
  4. Mallinckrodt Enterprises LLC $546 28 payments
  5. Allergan Inc. $529 64 payments
  6. Teva Pharmaceuticals USA, Inc. $527 54 payments
  7. AbbVie, Inc. $392 21 payments
  8. Amgen Inc. $275 13 payments
  9. Neurocrine Biosciences, Inc. $265 14 payments
  10. Genzyme Corporation $165 9 payments
  11. Other $1,113 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $6,333 434 payments
Products named General payments · program years 2019–2023
  1. Soliris $1,015 84 payments
  2. ACTHAR Immunology $939 53 payments
  3. OCREVUS $567 35 payments
  4. ACTHAR Autoimmune And Rare Disease $546 28 payments
  5. BOTOX $333 48 payments
  6. AIMOVIG $275 13 payments
  7. UBRELVY $242 14 payments
  8. AJOVY Central Nervous System $232 24 payments
  9. INGREZZA $187 10 payments
  10. Ajovy Central Nervous System $179 19 payments
  11. Other $1,912 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

434 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record